Mephedrone, the new drug to hit the party scene in the UK, will soon make its appearance across the pond, say experts. Mephedrone, also known as Meow, Drone or Bubble, may reach our shores in a matter of months, say experts. The latest drug to hit the party/club scene in the UK is currently the most popular of a number of “legal highs”.
Although many of these drugs have since been banned, Mephedrone is currently only under review. Sold legally as a plant food, it has been linked to at least two deaths.
Mephedrone has already been banned in Denmark, Estonia, Germany, Sweden and the Channel Island of Jersey.
According to Health Canada, it is a controlled substance, but researchers say, according to the Globe and Mail, that nonetheless the drug has been found here.
Mephedrone is a synthetic stimulant, a member of a new generation of drugs synthesized, experts say, by chemists in China and Southeast Asia. A cross between ecstasy and cocaine, it produces a sense of euphoria, heightened alertness, lowered inhibitions and increased talkativeness.
Mephedrone is a white, off-white, or sometimes yellowish powder that is snorted or swallowed from wraps of paper. Side effects, however, include anxiety, depression, short-term memory loss, heart palpitations, excessive sweating, headaches, and blurred vision. The drug is also particularly dangerous as many users report that once started, it is very hard to stop, leading to insomnia and hallucinogens.
Possibly most dangerous of all, Mephedrone is sold online legitimately and cheaply, making it both easily and widely available.
Highly addictive, the drug poses also quite a high risk of overdose and
addiction.
Last year, the drug was hardly known in the UK. One year later, it has quickly become a favourite among drug users in the club scene. A recent survey found that it is now the fourth most popular drug, with 41.7 percent of respondents reporting to have tried it, and 33.6 percent having used it in the last 30 days.
Read user testimonials gathered by the BBC News.
Source: The Globe and Mail and The Guardian 